The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
The First Frontier: Digital Biomarkers for Neurodegenerative Disorders
Open accessAbstract
Current measures of neurodegenerative diseases are highly subjective and based on episodic visits. Consequently, drug development decisions rely on sparse, subjective data, which have led to the conduct of large-scale phase 3 trials of drugs that are likely not effective. Such failures are costly, deter future investment, and hinder the development of treatments. Given the lack of reliable physiological biomarkers, digital biomarkers may help to address current shortcomings. Objective, high-frequency data can guide critical decision-making in therapeutic development and allow for a more efficient evaluation of therapies of increasingly common disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The promise of digital biomarkers to create a paradigm shift in biomedical research and clinical treatment monitoring is evident.3”
From Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial (2018) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Adams, J., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W. Y., Goldenthal, S. B., Biglan, K., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,190
Self-citationThe State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 917
Technology in Parkinson’s disease: challenges and opportunities
Espay, A. J., Bonato, P., Nahab, F. B., Maetzler, W., Dean, J. M., Klucken, J., Eskofier, B. M., Merola, A., Horak, F., Lang, A. E., et al. (2016) · Movement Disorders · doi:10.1002/mds.26642 · Cited by 654
Self-citationIsosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield, M. M., Anstrom, K. J., Levine, J. A., Koepp, G. A., Borlaug, B. A., Chen, H. H., LeWinter, M. M., Joseph, S. M., Shah, S. J., Semigran, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510774 · Cited by 556
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease
The Parkinson Study Group QE3 Investigators, Beal, M. F., Oakes, D., Shoulson, I., Henchcliffe, C., Galpern, W. R., Haas, R., Juncos, J. L., Nutt, J. G., Voss, T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.131 · Cited by 410
Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study
Arora, S., Venkataraman, V., Zhan, A., Donohue, S., Biglan, K. M., Dorsey, E. R., & Little, M. A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.026 · Cited by 387
Self-citationThe role of radiotracer imaging in Parkinson disease
Ravina, B. M., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., DHAWAN, V. M., Feigin, A., Fahn, S., Guttman, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149403.14458.7f · Cited by 372
Self-citationA randomized, placebo-controlled trial of coenzyme Q 10 and remacemide in Huntington’s disease
The Huntington Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.397 · Cited by 312
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
Farlow, M. R., Arnold, S. E., van Dyck, C. H., Aisen, P. S. S., Snider, B. J., Porsteinsson, A. P., Friedrich, S. W., Dean, R. A., Gonzales, C., Sethuraman, G., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.224 · Cited by 285
Automated Assessment of Bradykinesia and Dyskinesia in Parkinson's Disease
Griffiths, R. I., Kotschet, K. E., Arfon, S., Xu, Z. M., Johnson, W. G., Drago, J., Evans, A. H., Kempster, P. A., Raghav, S., & Horne, M. K. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-11071 · Cited by 278
Post, B., Merkus, M. P., de Bie, R. M. A., de Haan, R. J., & Speelman, J. D. (2005) · Movement Disorders · doi:10.1002/mds.20640 · Cited by 276
Torous, J., Staples, P., Shanahan, M., Lin, C., Peck, P., Keshavan, M., & Onnela, J.-P. (2015) · JMIR Mental Health · doi:10.2196/mental.3889 · Cited by 258
Cudkowicz, M., van den Berg, L. H., Shefner, J. M., Mitsumoto, H., Mora, J. S., Ludolph, A. C., Hardiman, O. M., Bozik, M. E., Ingersoll, E. W., Archibald, D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70221-7 · Cited by 232
Godinho, C., Domingos, J., Cunha, G., Santos, A. T., Fernandes, R. M., Abreu, D., Gonçalves, N., Matthews, H., Isaacs, T., Duffen, J., et al. (2016) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/s12984-016-0136-7 · Cited by 226
A randomized clinical trial of coenzyme Q 10 and GPI-1485 in early Parkinson disease
The NINDS NET-PD Investigators (2007) · Neurology · doi:10.1212/01.wnl.0000250355.28474.8e · Cited by 220
Kieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207
Self-citationMultiple sclerosis: the role of MR imaging.
Ge, Y. (2006) · PubMed Central · Cited by 196
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
Cudkowicz, M., Bozik, M. E., Ingersoll, E. W., Miller, R. G., Mitsumoto, H., Shefner, J. M., Moore, D. H., Schoenfeld, D., Mather, J. L., Archibald, D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2579 · Cited by 178
de Yébenes, J. G., Landwehrmeyer, G. B., Squitieri, F., Reilmann, R., Rosser, A., Barker, R. A., Carsten Saft, C., Magnet, M. K., Sword, A., Rembratt, Å., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70233-2 · Cited by 171
A clinical view on the development of technology‐based tools in managing Parkinson's disease
Maetzler, W., Klucken, J., & Horne, M. (2016) · Movement Disorders · doi:10.1002/mds.26673 · Cited by 162
Nelson, A. J., Zwick, D., Brody, S., Doran, C., Pulver, L., Rooz, G., Sadownick, M., Nelson, R. M., & Rothman, J. (2002) · Neurorehabilitation · doi:10.3233/nre-2002-17312 · Cited by 158
Clinician versus machine: Reliability and responsiveness of motor endpoints in Parkinson's disease
Heldman, D. A., Espay, A. J., LeWitt, P. A., & Giuffrida, J. P. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.022 · Cited by 156
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry, A. J., McDermott, M., Kieburtz, K. D., de Blieck, E. A., Beal, F. M., Marder, K. S., Ross, C. A., Shoulson, I., Gilbert, P. R., Mallonee, W. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003478 · Cited by 139
Self-citationA randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease
The Huntington Study Group HART Investigators (2013) · Movement Disorders · doi:10.1002/mds.25362 · Cited by 127
Natural History of Huntington Disease
Dorsey, E. R. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4408 · Cited by 124
Self-citationFeasibility of home-based automated Parkinson's disease motor assessment
Mera, T. O., Heldman, D. A., Espay, A. J., Payne, M., & Giuffrida, J. P. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.09.019 · Cited by 111
A Randomized, Placebo-Controlled Trial of Latrepirdine in Huntington Disease
Kieburtz, K. D. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.334 · Cited by 92
Self-citationStamford, J. A., Schmidt, P. N., & Friedl, K. E. (2015) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2015.2464354 · Cited by 88
A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease
Reilmann, R., Rouzade‐Dominguez, M., Carsten Saft, C., Süßmuth, S. D., Priller, J., Rosser, A., Rickards, H. E., Schöls, L. J., Pezous, N., Gasparini, F., et al. (2015) · Movement Disorders · doi:10.1002/mds.26174 · Cited by 79
Palmer, J. L., Coats, M. A., Roe, C. M., Hanko, S. M., Xiong, C., & Morris, J. C. (2010) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2010.05313.x · Cited by 78
Daytime sleep in Parkinson's disease measured by episodes of immobility
Kotschet, K. E., Johnson, W. G., McGregor, S., Kettlewell, J., Kyoong, A., O’Driscoll, D. M., Turton, A. R., Griffiths, R. I., & Horne, M. K. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.011 · Cited by 73
Sleep disorders in neurodegenerative diseases
Raggi, A., & Ferri, R. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03034.x · Cited by 68
Wearable Sensors in Huntington Disease: A Pilot Study
Andrzejewski, K. L., Dowling, A. V., Stamler, D. A., Felong, T. J., Harris, D. A., Wong, C., Cai, H. W., Reilmann, R., Little, M. A., Gwin, J. T., et al. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160197 · Cited by 67
Self-citationOssig, C., Gandor, F., Fauser, M., Bosredon, C., Churilov, L. P., Reichmann, H., Horne, M. K., Ebersbach, G., & Storch, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161559 · Cited by 64
The Impact of Exercise, Cognitive Activities, and Socialization on Cognitive Function
Jedrziewski, M. K., Ewbank, D. C., Wang, H., & Trojanowski, J. Q. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513518646 · Cited by 59
(2012) · JAMA Neurology · doi:10.1001/2013.jamaneurol.382 · Cited by 53
Sampaio, C., Borowsky, B., & Reilmann, R. (2014) · Movement Disorders · doi:10.1002/mds.26021 · Cited by 50
Interpretation of clinical trials that stopped early
Viele, K., McGlothlin, A., & Broglio, K. (2016) · JAMA · doi:10.1001/jama.2016.2628 · Cited by 48
Digitomotography in Parkinson’s Disease: A Cross-Sectional and Longitudinal Study
Maetzler, W., Ellerbrock, M., Heger, T., Saß, C., Berg, D., & Reilmann, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123914 · Cited by 24
WiiPD — An approach for the objective home assessment of Parkinson's disease
Synnott, J., Chen, L., Nugent, C., & Moore, G. (2011) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2011.6090666 · Cited by 15
Joining forces to fight neurodegenerative diseases
Neurology, T. L. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70004-8 · Cited by 8
Research works printed but not linked: 1
- 10.1001/jama.2015.120 · DOI · Paper page
Cited by
Sorted by citations
Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity
Kourtis, L. C., Regele, O. B., Wright, J. M., & Jones, G. B. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0084-2 · Cited by 476
Digital Twins for Multiple Sclerosis
Voigt, I., Inojosa, H., Dillenseger, A., Haase, R., Akgün, K., & Ziemssen, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669811 · Cited by 294
Lipsmeier, F., Taylor, K. I., Kilchenmann, T., Wolf, D., Scotland, A., Schjodt‐Eriksen, J., Cheng, W., Fernandez‐Garcia, I., Siebourg‐Polster, J., Jin, L., et al. (2018) · Movement Disorders · doi:10.1002/mds.27376 · Cited by 266
“The promise of digital biomarkers to create a paradigm shift in biomedical research and clinical treatment monitoring is evident.(3) Our study demonstrates that digital biomarkers have now become feasible.”
BackgroundTeleneurology and mobile technologies: the future of neurological care
Dorsey, E. R., Glidden, A. M., Holloway, M. R., Birbeck, G. L., & Schwamm, L. H. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.31 · Cited by 258
Self-citationPowers, R., Etezadi‐Amoli, M., Arnold, E. M., Kianian, S., Mance, I., Gibiansky, M. L., Trietsch, D., Alvarado, A. S., Kretlow, J. D., Herrington, T. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7865 · Cited by 204
Metadata
- Authors
- Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K.
- Affiliations
- University of Rochester Medicine (US)
- Venue
- Digital Biomarkers
- Publisher
- S. Karger AG
- Published
- 2017-07-04
- Volume
- 1
- Issue
- 1
- Pages
- 6-13
- ISSN
- 2504-110X (ISSN-L)
- PMC
- PMC7015357
- OpenAlex
- W2732150368
- Cited by
- 162
- References
- 48
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 18 · 2023: 19 · 2022: 28 · 2021: 18 · 2020: 12 · 2019: 12 · 2018: 6 · 2017: 1
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Digital Biomarkers (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (P20NS092529)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Mental Health Research Topics
- Social Sciences › Psychology › Applied Psychology › Digital Mental Health Interventions
- Keywords
- neurodegenerative diseases, disease progression monitoring, drug development, objective outcome measures, treatment evaluation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
